DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oral and IV Baclofen in Adult Volunteers

Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Baclofen Withdrawal Syndrome

Intervention: Oral baclofen (Drug); Intervenous baclofen (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: University of Minnesota - Clinical and Translational Science Institute


The primary objective of this study is to characterize baclofen pharmacokinetics following oral and intravenous administration in patients who are on chronic oral baclofen therapy. The secondary objective is to determine the safety profile of an IV baclofen formulation. This study is a randomized crossover study with two treatment arms. All subjects will receive a dose of oral baclofen and a dose of IV baclofen on separate study days. Whether the oral or intravenous form is given on the first study day will be randomized in a 1: 1 manner. The pharmacokinetic and tolerability information gained from this study will support the development of further studies to assess the use of IV baclofen to prevent or treat baclofen withdrawal syndrome.

Clinical Details

Official title: Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

oral bioavailability

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

Plasma Decay Half-Life (t1/2)

Maximum concentration (Cmax)


Secondary outcome:

assessment of sedation



blood pressure


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: Subjects will be eligible to participate in the study if all of the following conditions exist: 1. Males and females between the ages of 18-65. 2. Subjects are capable of giving informed consent. 3. Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide. 4. Subject should be medication free, other than study drug, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI.


Exclusion Criteria: Subjects will be excluded from participation in the study if any of the following conditions exist: 1. Women who are pregnant. 2. Women who are breast feeding. 3. Subject has a history of intolerance to IV administration of medication. 4. Subject has a known hypersensitivity to baclofen. 5. Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease 6. Subject has taken or used any investigational drug or device in the 30 days prior to screening. 7. Subject has taken either prescribed or over the counter medication for 48 hours prior to baclofen administration on either of the study days. 8. Subject reveals clinically significant abnormalities on screening laboratory tests. 9. Subject is a non-English speaker, such that ability to ascertain neurological status would require an interpreter.

Locations and Contacts

University of Minnesota, Minneapolis, Minnesota 55455, United States
Additional Information

Starting date: January 2013
Last updated: August 4, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017